Enliven Therapeutics, Inc.
corporate_fare Company Profile
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ELVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ELVN spans 10-Q, 8-K, SCHEDULE 13D/A, 144.
Recent high-impact activity:
- Enliven 10-Q: Q3 Loss Widens to $27.7M, $884.4M Cash Funds Operations Into 2030
- Enliven Posts Q3 Loss, $884M Cash and Runway Into 2030 Ahead of ENABLE-2 Launch
- FDA Signs Off on Phase 3 Trial Design for Enliven's Relcobatinib in CML
- OrbiMed Reduces Stake in Enliven Therapeutics by Over 1%
- Institutional Investor OrbiMed Files Intent to Sell $38.3M in Enliven Therapeutics Stock
Financial Snapshot
Short Interest & Short Volume
5.69 days to coverFINRA reported short interest of 10,293,807 shares in ELVN as of the October 30, 2026 settlement, a 10.3% increase from the prior period — about 5.7 days to cover at its recent average daily volume. On November 20, 2026, 84.8% of ELVN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for ELVN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.
Offering Finalized and Upsized · Pricing Details
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →